U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast CancerHarpreet Singh, Richard Pazdur, Shenghui Tang et al.|Clinical Cancer Research|2018Cited by 98
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell CarcinomaHarpreet Singh, Richard Pazdur, Michael H. Brave et al.|Clinical Cancer Research|2016Cited by 54